Zydus Lifesciences Ltd. has entered into a Business Transfer Agreement (“BTA”) for the purchase of one of Watson Pharma Private Limited’s Business Undertakings (“Watson”) on a going-concern basis through a slump sale, without assigning values to specific assets and liabilities, on a cash-free and debt-free basis, at a lump-sum consideration of Rs. 46.77 crores.
The Watson Business Undertaking is in the business of creating, producing, marketing, and selling active pharmaceutical ingredients (“APIs”). There were no external sales to outside parties because the Business Undertaking catered to the Teva group’s API needs.